Not applicableUnknownNCT05559528What this trial is testingBRaziLian outcomE for metAStatic breasT CancerWho this might be right forMetastatic Breast CancerBreast Cancer Stage IV Hospital do Coracao 300
Not applicableNot Yet RecruitingNCT06810492What this trial is testingThe Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant TreatmentWho this might be right forBreast Cancer Stage IIIBreast Cancer Stage II Hongmei Zheng, PhD 40
Large-scale testing (Phase 3)Looking for participantsNCT05901428What this trial is testingTCb vs EC-T in High Risk ER+/HER2- Breast CancerWho this might be right forHormone Receptor Positive HER-2 Negative Breast Cancer Fudan University 1,736
Testing effectiveness (Phase 2)Study completedNCT00618657What this trial is testingCarboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant SettingWho this might be right forBreast CancerHER2-negative Breast CancerHER2-positive Breast Cancer+7 more University of California, Irvine 127
Large-scale testing (Phase 3)Active Not RecruitingNCT04906395What this trial is testingOvarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast CancerWho this might be right forBreast Cancer Tolmar Inc. 250
Early research (Phase 1)Active Not RecruitingNCT03939897What this trial is testingTesting the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast CancerWho this might be right forAnatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic HER2-Negative Breast Carcinoma+2 more National Cancer Institute (NCI) 24
Testing effectiveness (Phase 2)Looking for participantsNCT06923527What this trial is testingCirculating Tumor DNAWho this might be right forER+ Breast Cancer Yale University 50
Testing effectiveness (Phase 2)Study completedNCT02441946What this trial is testingA Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast CancerWho this might be right forBreast CancerHormone Receptor Positive TumorEarly-Stage Breast Carcinoma Eli Lilly and Company 224
Testing effectiveness (Phase 2)Study completedNCT02258451What this trial is testingStudy of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast CancerWho this might be right forBreast Neoplasms Bayer 283
Testing effectiveness (Phase 2)Looking for participantsNCT05594095What this trial is testingSNF Platform Study of HR+/ HER2-advanced Breast CancerWho this might be right forBreast NeoplasmBreast CancerHormone Receptor Positive Tumor+2 more Fudan University 620
Post-approval studies (Phase 4)WithdrawnNCT03988114What this trial is testingAbemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast CancerWho this might be right forMetastatic Breast Cancer Eli Lilly and Company
Testing effectiveness (Phase 2)Active Not RecruitingNCT05558722What this trial is testingAnlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast CancerWho this might be right forBreast Cancer Stage II Xijing Hospital 31
Testing effectiveness (Phase 2)Study completedNCT03481998What this trial is testingSHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast CancerWho this might be right forAdvanced Breast Cancer Jiangsu HengRui Medicine Co., Ltd. 104
Testing effectiveness (Phase 2)Looking for participantsNCT06201234What this trial is testingEvaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast CancerWho this might be right forHormone Receptor Positive HER-2 Negative Breast CancerAdvanced or Metastatic Breast CancerBRCA1 Mutation+1 more GBG Forschungs GmbH 176
Testing effectiveness (Phase 2)Looking for participantsNCT06369285What this trial is testingAlisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerWho this might be right forHormone Receptor Positive HER-2 Negative Breast CancerMetastatic Breast CancerRecurrent Breast Cancer Puma Biotechnology, Inc. 225
Not applicableApproved For MarketingNCT02792725What this trial is testingExpanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast CancerWho this might be right forMetastatic Breast Cancer Eli Lilly and Company
Not applicableLooking for participantsNCT06781281What this trial is testingNabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.Who this might be right forBreast Cancer Invasive Henan Cancer Hospital 709
Testing effectiveness (Phase 2)Active Not RecruitingNCT03393845What this trial is testingStudy of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer PatientsWho this might be right forBreast Cancer Nancy Chan, MD 47
Very early researchEnded earlyNCT03361800What this trial is testingWindow of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBCWho this might be right forBreast CancerInvasive Breast CancerER-Negative PR-Negative HER2-Negative Breast Cancer UNC Lineberger Comprehensive Cancer Center 5
Not applicableStudy completedNCT01293032What this trial is testingHormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast CancerWho this might be right forDuctal Breast Carcinoma in SituLobular Breast Carcinoma in SituStage II Breast Cancer+4 more Virginia Commonwealth University 59